Coherus BioSciences Inc (NAS:CHRS)
$ 1.76 -0.06 (-3.3%) Market Cap: 201.92 Mil Enterprise Value: 429.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 05:00PM GMT
Release Date Price: $16.43 (+0.31%)
Chris McCarthy

Thank you all for joining Day 3 of the Bank of America Health Care Conference. Up next, we have Coherus BioScience.

Presenting will be Denny Lanfear, CEO. This is Chris McCarthy speaking from the equity sales and trading desk. I'm a specialty salesperson in health care. Denny will be presenting, but you can ask questions via Veracast which, if there are any at the end, we will post to management.

Denny, thanks so much.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you very much. Let me first start my remarks indicating that all statements made by the company are forward-looking statements. They are subject to the customary qualifications and all statements made are subject to the company's SEC filings, including our most recent. Thank you.

So let me first talk a little bit about the company's position with UDENYCA, which has been the most successful biosimilar product to date and how the company intends to leverage the success of UDENYCA across a broad range of other biosimilars over the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot